Home/Amphista Therapeutics/Martin Pass PhD

MP

Martin Pass PhD

Chief Development Officer

Amphista Therapeutics

Therapeutic Areas

Oncology Immunology Neuroscience

Amphista Therapeutics Pipeline

Drug	Indication	Phase
BRD9 Degrader	Acute Myeloid Leukaemia (AML)	Pre-clinical
SMARCA2 Degrader	Non-Small Cell Lung Cancer (NSCLC) with CNS metastasis potential	Lead Optimisation

Leadership Team at Amphista Therapeutics

Louise Modis PhD

Chief Executive Officer

Giles Brown PhD

Executive VP Drug Discovery

View full Amphista Therapeutics profile